



Fourth annual meeting of the network of Buruli ulcer PCR laboratories in the WHO African Region

Mundi complex, Yaoundé,
24–26 October 2022

**Fourth annual meeting of
the network of Buruli ulcer
PCR laboratories in the
WHO African Region**

**Mundi complex, Yaoundé,
24–26 October 2022**

Fourth annual meeting of the network of Buruli ulcer PCR laboratories in the WHO African Region, Mundi complex, Yaoundé, 24-26 October 2022

ISBN 978-92-4-007791-1 (electronic version)

ISBN 978-92-4-007792-8 (print version)

© World Health Organization 2023

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Fourth annual meeting of the network of Buruli ulcer PCR laboratories in the WHO African Region, Mundi complex, Yaoundé, 24-26 October 2022. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <https://www.who.int/publications/book-orders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the report of the fourth annual meeting of the network of Buruli ulcer PCR laboratories in the WHO African Region and does not necessarily represent the decisions or the policies of WHO.

Photo cover: © WHO

Design by Big Mouth Gets Ltd

Layout by Imprimerie Centrale

Contents

Acknowledgements	iv
Abbreviations and acronyms	v
1. Introduction	2
2. Objectives of the meeting	6
3. Topics for discussion	10
3.1 Epidemiology and geographical distribution of skin NTDs in the WHO African and Eastern Mediterranean regions	10
3.2 BU-LABNET activities	10
3.3 Member laboratory activities including research	10
3.4 PCR protocols for cutaneous leishmaniasis, mycetoma and yaws	11
3.5 SwiftX technology	11
3.6 Priority skin NTDs for integration in the different network laboratories	11
3.7 Perspectives for collaborative studies	11
4. Recommendations and activities to be carried out in 2023	16
4.1 For the Coordinating Centre	16
4.2 For member laboratories	16
4.3 For national Buruli ulcer control programmes	16
4.4 For partners	16
4.5 For WHO	16
5. Closing remarks and next meeting	20
References	21

Annexes

Annex 1. Agenda	22
Annex 2. List of participants	23
Annex 3. BU-LABNET membership certificate	26
Annex 4. Meeting photographs	27

Acknowledgements

The World Health Organization (WHO) is grateful to the participants of the fourth (hybrid) meeting of the network of Buruli ulcer PCR laboratories (BU-LABNET) in Africa at the Mundi complex in Yaoundé, Cameroon, on 24–26 October 2022.

The meeting was organized by the Pasteur Centre of Cameroon (CPC) and the WHO Department of Control of Neglected Tropical Diseases (WHO/NTD), supported by the Anesvad Foundation and American Leprosy Missions.

The report was prepared by Mr Hycenth Numfor and Dr Sara Eyangoh (BU-LABNET Coordinating Centre, CPC) and reviewed by the meeting participants and the BU-LABNET advisory board. Dr Kingsley Asiedu (WHO/NTD) provided technical oversight along with Dr Priya Pathak (WHO/NTD). Ms Félicité Bana Owona and the CPC Communications Department gave administrative support.

Funding for the meeting was provided by the Anesvad Foundation, the Raoul Follereau Foundation and the American Leprosy Missions.

Abbreviations and acronyms

BU-LABNET	Buruli ulcer laboratory network
COVID-19	coronavirus disease
CPC	Pasteur Centre of Cameroon
ITM	Institute of Tropical Medicine
NTD	neglected tropical disease
PCR	polymerase chain reaction
SOP	standard operating procedure
WHO	World Health Organization

A photograph of an office environment, partially obscured by a dark green overlay. In the background, a blue bulletin board is visible with several white papers pinned to it using yellow pushpins. To the right, a black office chair is partially visible. The overall scene suggests a professional or academic setting.

01

Introduction



© WHO/Ernest Ankomah

02

Introduction

In October 2019, WHO convened the first meeting of the Buruli ulcer laboratory network (BU-LABNET) in Yaoundé, Cameroon, bringing together 11 laboratories from nine countries at the Pasteur Centre of Cameroon (CPC), the network's Coordinating Centre. The network was formally established at this meeting (1) and its members were those present. The objective of BU-LABNET is to improve diagnosis of Buruli ulcer based on polymerase chain reaction (PCR) using standardized testing protocols, involving external quality assurance programmes and sharing knowledge among member laboratories.

In July 2020 and December 2021, two further meetings were held virtually owing to the coronavirus disease (COVID-19) pandemic and associated disruptions. Given the gradual easing of COVID-19 restrictions and resumption of activities, it was decided to organize the fourth meeting onsite, with online participation for those unable to attend in person.

The fourth annual meeting of BU-LABNET was held at the Mundi complex in Yaoundé, Cameroon, on 24–26 October 2022. The meeting agenda is attached as Annex 1 and the participants are listed in Annex 2.



02

Objectives of the
meeting



© WHO/Kingsley Asiedu

03

Objectives of the meeting

The overall objective of the meeting was to review the progress of BU-LABNET and plan activities for 2023.

The specific objectives were:

- to present updates on activities including challenges encountered;
- to share ideas on how to enhance the visibility of the network through collaborative studies and publications;
- to discuss the integration of PCR-based case confirmation with that for other skin-related neglected tropical diseases (skin NTDs);
- to review and adopt the updated standard operating procedures (SOPs) for Buruli ulcer;
- to brainstorm on concrete activities to implement in 2023; and
- to discuss harmonization of procedures for PCR-based diagnosis of yaws.



03

Topics for discussion



© WHO/Simon Lim

04

Topics for discussion

The following topics were reviewed and discussed:

- epidemiology and geographical distribution of skin NTDs in WHO's African and Eastern Mediterranean regions;
- BU-LABNET activities including those conducted by the Coordinating Centre, and challenges and status of member laboratories;
- activities of member laboratories, including research;
- PCR protocols for yaws, cutaneous leishmaniasis and mycetoma;
- SwiftX technology;
- integration of priority skin NTDs in the different network laboratories; and
- perspectives for collaborative studies.

3.1 Epidemiology and geographical distribution of skin NTDs in the WHO African and Eastern Mediterranean regions

Dr Augustin Kadima and Dr Yves Barogui (WHO Regional Office for Africa) presented the epidemiology and geographical distribution of Buruli ulcer, yaws, leprosy and cutaneous leishmaniasis in the WHO African Region. Professor Ahmed Fahal (Mycetoma Research Center) presented the mycetoma situation in the WHO Eastern Mediterranean Region. The NTD road map targets for 2030 (2) were also presented.

3.2 BU-LABNET activities

Dr Sara Eyangoh (BU-LABNET programme coordinator) summarized the milestones registered to date. The main challenge raised was that of communication to enhance the visibility of the network's activities. The strengths of the 11 member laboratories and areas for improvement are shown in Fig. 1.

The formal status of member laboratories was raised as an important issue, and it was agreed to establish a membership certificate (Annex 3). Certificates were duly produced, signed and awarded to all the member laboratories present at the meeting.

Revisions to the SOPs of the network were discussed. The SOPs were shared before the meeting with member

laboratories for review and feedback. All comments were consolidated and re-shared with members before a final consolidated version 2 was prepared.

3.3 Member laboratory activities including research

Representatives from the member laboratories of the network presented updates of their activities using the reporting template. Discussions focused on PCR test statistics for 2022, challenges, planned activities for 2023 and perspectives from the individual laboratories.

It was noted that:

- the number of samples received and tested by laboratories has fallen; and
- laboratories require additional training or refresher on diagnosis of Buruli ulcer.

During the update on research activities, five laboratories presented ongoing research studies, including general objectives, collaborating teams, results (if any) and next steps.

Dr Dziejdom de Souza (Foundation for Innovative New Diagnostics [FIND]) shared progress on research titled "A Buruli ulcer mycolactone rapid diagnostic test to enhance early diagnosis and treatment" implemented in Cameroon and Côte d'Ivoire.

Dr Michael Frimpong (Kumasi Centre for Collaborative Research in Tropical Medicine) presented on the "Development and validation of a portable, point-of-need *Mycobacterium ulcerans* qPCR test" study carried out in Cameroon and Ghana.

Both studies aim to decentralize diagnosis of Buruli ulcer to peripheral laboratories to facilitate access to diagnosis.

Dr Richard Akuffo (Noguchi Memorial Institute for Medical Research) discussed global perspectives and research history of cutaneous leishmaniasis in Ghana and summarized recent research conducted in the Oti Region of Ghana.

Strengths	Areas for improvement
<ul style="list-style-type: none"> • Motivated staff performing PCR for BU in all the laboratories • Well characterized three-room set-up for quantitative PCR-based diagnosis (10/11) • Turnaround time for result delivery is within a week on average (9/11) • BU-LABNET SOPs available and used by all laboratories 	<ul style="list-style-type: none"> • Personnel capacity building (refresher) on the PCR technique (3/11) • Equipment maintenance, calibration and certification (9/11) • New batch reagent validation prior to use, and general inventory of BU materials (9/11)

Fig. 1. BU-LABNET strengths and areas for improvement

The network offers an important opportunity to conduct or participate in multicentric research activities, including clinical trials evaluating new drug treatments, diagnostic tools, molecular epidemiology and mapping studies, as well as surveillance of antimicrobial resistance. Some member laboratories are already carrying out research studies in collaboration with other institutions and/or partners.

3.4 PCR protocols for cutaneous leishmaniasis, mycetoma and yaws

The vision of the network is to integrate other skin NTDs in the Buruli ulcer platform. As countries with diagnostic capacity for these diseases are identified, existing PCR protocols will be harmonized using the same approach as for the PCR-based protocols for Buruli ulcer. A session was thus dedicated for presentations of diagnostic protocols currently used for yaws, cutaneous leishmaniasis and mycetoma.

Dr Serges Tchatchouang (CPC) presented the yaws PCR protocols.

Dr Sara Eyangoh (CPC) spoke about the implementation of yaws differential diagnosis, specifically the detection of *Haemophilus ducreyi*.

Dr Javier Moreno and Dr Carmen Chicharro (Carlos III Health Institute) presented the PCR protocols for cutaneous leishmaniasis.

Dr Wendy van de Sande (Erasmus Medical Center) and Professor Ahmed Fahal (Mycetoma Research Center) presented the PCR protocols for mycetoma.

To address the geographical distribution of mycetoma in the different endemic countries and the prevalent pathogens therein, it would be important to conduct a study to demonstrate evidence of the majority of the identified mycetoma pathogens. It would also be necessary to conduct a molecular identification survey for mycetoma to show evidence of the specific pathogens prevalent in endemic countries.

3.5 SwiftX technology

Dr Andy Wende (Xpedite Diagnostics GmbH) described the SwiftX technology and the advantages of the DNA extraction kits.

The presentations are available online (3). Photographs of the participants are shown in Annex 4.

3.6 Priority skin NTDs for integration in the different network laboratories

The possibility of advancing the current platform to capture the new vision of the network – integrating other skin NTDs into the Buruli ulcer platform – was discussed with the experts on yaws, cutaneous leishmaniasis, mycetoma and leprosy.

Integration will consider disease epidemiology in each of the network countries, sampling techniques, PCR testing and standard protocols available for each disease. This implies the importance of a needs assessment to guide future actions. It was agreed to start integration with yaws.

3.7 Perspectives for collaborative studies

Four working groups were created (Fig. 2). The discussion was led by Professor Richard Phillips (Kumasi Centre for Collaborative Research in Tropical Medicine). The recommendations arising from the group discussions are summarized below.

3.7.1 Group 1 discussion and recommendations

The group is expected to develop guidance that includes the objectives of the collaborative study, the expected results and the implementation strategy.

Recommendations

- Perform a review of non-*M. ulcerans* ulcers.
- Explore any potential collaboration for mycetoma using artificial intelligence.




Fig. 2. BU-LABNET working groups for collaborative studies

- Investigate the causes of ulcers not due to Buruli ulcer, yaws, cutaneous leishmaniasis and mycetoma or from *H. ducreyi*.
- Share images and data of chronic wounds in question with the network.
- Develop a differential diagnosis for each skin NTD.

3.7.2 Group 2 discussion and recommendations

FIND and WHO already support the development of some assays (prototype methods available), and the network could be partners in evaluating these diagnostic tools.

Recommendations

- Optimize evaluation protocols (the network should work on this).
- Consider signing an agreement to share samples available in countries among the laboratories.
- Develop a material transfer agreement and an SOP for sample conservation.

3.7.3 Group 3 discussion and recommendations

The existing tools for transmission research have been exhausted. Besides whole genome sequencing, other approaches may not address the distribution of *M. ulcerans* or identify potential reservoirs of bacterium.

Recommendations

- Investigate available studies on the risk factors of mycetoma transmission.
- Propose a study to sample the asymptomatic families of affected persons.

3.7.4 Group 4 discussion and recommendations

The main role of the network laboratories in different treatment studies would be to provide diagnostics. Also, the network website could be updated with post-research proposals; interested persons will join the discussions.

Recommendations

- Identify the role of the network in different treatment studies.
- Share post-research proposals on the network's website to facilitate submitting research proposals and advancing work.

Additional group work on the **visibility of the network** was presented by Professor Phillips and is summarized in the Table below. The target audience is funders, scientific community, national programmes, media, biotech companies, health ministries, other networks, organizations and the general public.

Table. Measurement of success and responsibilities, by activity

Activity	How do we want to measure success?	Who is responsible?
Website	Track site visits.	Coordinating Centre Web designer and content builder Remote developer/designer and maintenance
	Provide regular updates (photos on website, member laboratory posts network activities, member laboratory profiling, link of published articles, post grant awards or other achievements, short statements from scientist on the work of the network, regular scientific interviews about activities of the network, information on skin NTDs for public education, link website to other social media platforms (e.g. Twitter, LinkedIn – Institutional website should have a link to the network website)).	Network members Coordinating Centre Anesvad Foundation communication department
Social media handles (Twitter, Facebook, LinkedIn, WhatsApp)	Provide website link to tweets or other posts on social media. Post quarterly/biannual quizzes on social media handles for young upcoming scientists.	Member laboratories Coordinating Centre Partners
Scientific publications	Track publications by network members.	Coordinating Centre/scientists Partners
Presence at large meetings (e.g. WHO, ASTMH, ECMID, WHS)	Maximize number of and participation at meetings.	Coordinating Centre Member laboratories Partners
Prepare fliers/posters for major meetings (e.g. WHO, ASTHM)	Track the numbers of fliers and posters. Print and distribute to laboratories (in English and French) in high resolution.	Coordinating Centre Partners
Organize webinars on the activities of the network	Record the number of webinars organized. Host webinars on NTDs (ISNTD).	Coordinating Centre
	Design a course on molecular diagnosis of Buruli ulcer to post on the OpenWHO training platform.	Coordinating Centre Member laboratories for support Partners

ASTMH: American Society of Tropical Medicine and Hygiene; ECMID: European Congress of Clinical Microbiology and Infectious Diseases; ISNTD: International Society for Neglected Tropical Diseases; WHS: World Health Summit.



04

**Recommendations and
activities to be carried
out in 2023**



05

Recommendations and activities to be carried out in 2023

4.1 For the Coordinating Centre

- Implement activities to improve the visibility of, and communication around, the work of BU-LABNET. The focus here is to increase visibility among the general public through the website and social media.
- Finalize the reviewed SOPs on Buruli ulcer, obtain approval from the advisory board and distribute to member laboratories.
- Establish certificates of external quality assurance participation for distribution to participating laboratories in 2022.
- Finalize the global report of on-site laboratory evaluation of BU-LABNET member laboratories.
- Follow up on the harmonization of procedures to integrate skin NTDs under the responsibility of/in collaboration with disease experts.
- Promote all collaborative research on skin NTDs.
- Build an online system for laboratories to report data on their activities in DHIS2. This system would be used by laboratories in the network (laboratories in the WHO Region) to enter data which will then be transferred to the central database at the Coordinating Centre.
- Standardize data sharing agreements and material transfer agreements among the member laboratories to enhance collaborative work.
- Encourage best practices and research ethics for diagnosis and treatment of Buruli ulcer and other skin NTDs as prioritized by the network.

4.2 For member laboratories

- Commit to raising the visibility of BU-LABNET according to its activities and the established communication strategy.
- Continue to use the updated SOPs for diagnosis of Buruli ulcer and other skin NTDs as provided by the Coordinating Centre.
- Improve collaboration with national control programmes and convene in-country meetings to harmonize data on Buruli ulcer activities.
- Participate in the external quality assurance programme.

- Collaborate with the Coordinating Centre towards integrating other skin NTDs (*yaws, H. ducreyi, cutaneous leishmaniasis and leprosy*) in the Buruli ulcer PCR platform.
- Furnish the Coordinating Centre with working PCR protocols on *yaws, leprosy and cutaneous leishmaniasis* to help in the harmonization procedure.
- Make efforts to encourage research collaboration among member laboratories and to share opportunities for collaboration.
- Ensure timely reporting of laboratory PCR data on Buruli ulcer to the national programmes and the BU-LABNET Coordinating Centre.

4.3 For national Buruli ulcer control programmes

- Strengthen collaboration with BU-LABNET member laboratories in training field workers on activities against endemic skin NTDs.
- Promote active case searches among communities, harmonize sample collection techniques in facilities and ensure timely transfer of samples to member laboratories.

4.4 For partners

- Support the BU-LABNET Coordinating Centre to achieve its objectives on visibility, development of standard documents and coordination of scientific studies.
- Explore additional funding avenues to sustain network activities.

4.5 For WHO

- Help to raise awareness of BU-LABNET at all levels.
- Advocate for support of the network's activities.
- Share experiences from other laboratory networks (e.g. malaria and tuberculosis).
- Facilitate training of laboratories through the Coordinating Centre.

05

Closing remarks and
next meeting



© WHO/Stéphane Saporito



Closing remarks and next meeting

After the customary exchange of courtesies, the meeting was closed.

The next meeting will be held in Ghana on 23–25 October 2023.

References

1. First meeting of the network on Buruli ulcer PCR laboratories in the WHO African Region, Centre Pasteur du Cameroon, Yaoundé, 21–24 October 2019. Geneva: World Health Organization; 2020 (<https://apps.who.int/iris/handle/10665/333592>, accessed 23 June 2023).
2. Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021–2030. Geneva: World Health Organization; 2020 (<https://apps.who.int/iris/handle/10665/338565>, accessed 23 June 2023).
3. BU-LABNET 2022 presentations, recommendations and pictures (<https://www.dropbox.com/sh/8mi7lxdiq0cld8y/AAAHLUw3bN-K9BEbPTmofXYqa?dl=0>, accessed 23 June 2023).

Agenda

Day/Time	Topic	Speaker
Monday, 24 October 2022 (Day 1)		
09:00–09:30	Arrival of participants and registration	All
09:30–10:00	Opening ceremony Welcome speeches by the Centre Pasteur, WHO and MOH	Mirdad Kazanji Phanuel Habimana Minister of Public Health
10:40–12:40	Presentation on the epidemiology and geographical distribution of skin NTDs in Africa (AFRO and EMRO)	Yves Barogui Ahmed Fahal/Augustin Kadima
13:30–16:30	Updates on BU-LABNET activities Validation of the revised BU-LABNET SOPs Assessment of network laboratories: key findings Discussion on the laboratory network member status	Sara Eyangoh Hycenth Numfor All
16:30–17:00	Presentation of network laboratory activities Presentation plus discussion: 15 mins for each laboratory Discussion and closing	Network laboratories Kingsley Asiedu
Tuesday, 25 October 2022 (Day 2)		
08:30–09:30	Presentation of yaws qPCR protocols	Representative of yaws consortium
10:00–11:00	Discussion: Steps for implementation/integration of yaws in Buruli ulcer diagnosis platform	Representative of yaws consortium/Sara Eyangoh
11:00–11:30	Possible implementation of <i>Haemophilus ducreyi</i> and yaws differential PCR	Sara Eyangoh/representative of yaws consortium
11:30–13:00	Research updates by member laboratories	Network laboratories
14:00–15:00	Presentation of cutaneous leishmaniasis PCR protocols	Javier Moreno/Carmen Chicharro/Israel Cruz
15:00–16:00	Presentation of cutaneous mycetoma PCR protocols	Ahmed Fahal/Sahar Bakhiet Wendy van de Sande
16:00–17:00	Discussion and closing remarks	Kingsley Asiedu
Wednesday, 26 October 2022 (Day 3)		
08:30–09:30	Discussion on other priority skin NTDs to integrate in the different network laboratories	Invited experts on skin NTDs
10:00–10:30	Presentation of the SwiftX technology and advantages of the DNA extraction kits	Andy Wende
10:30–12:30	Discussion on development of collaborative studies: Working groups	Experts plus network laboratories
13:30–15:00	Restitution and discussion	All
15:00–16:00	Recommendations and closing remarks	Sara Eyangoh, Sundeep Vedithi

List of participants

BU-LABNET members

Benin

Ms Line-Marlène Ganlonon, Centre de Dépistage et de Traitement de l'Ulçère de Buruli, Pobè

Cameroon

Ms Brigitte Félicité Bana Owona, Centre Pasteur du Cameroun, Yaoundé

Mr Jude Alexis Bondi, Mycobacteriology Department, Centre Pasteur du Cameroun, Yaoundé

Dr Valérie Flore Donkeng Donfack, National Reference Laboratory for Tuberculosis and Buruli ulcer, Centre Pasteur du Cameroun, Yaoundé

Dr Sara Eyangoh, Buruli Ulcer Laboratory Network Coordinator, Centre Pasteur du Cameroun, Yaoundé

Mr Yannick Willy Kamdem Simo, Mycobacteriology Department, Centre Pasteur du Cameroun, Yaoundé

Mr Hycenth Numfor, Buruli Ulcer Laboratory Network, Centre Pasteur du Cameroun, Yaoundé

Dr Serges Tchatchouang, Centre Pasteur du Cameroun, Yaoundé

Côte d'Ivoire

Professor Solange Kakou Ngazoa, Institut Pasteur de Côte d'Ivoire, Abidjan

Mr Konan Albert Yavo, Plateforme de Biologie Moléculaire, Institut Pasteur de Côte d'Ivoire, Abijan

Democratic Republic of the Congo

Dr Marie José Kabedi, Institut National de Recherche Biomédicale, Kinshasa

Dr Nadine Mintsey, Institut national de Recherche Biomédicale, Kinshasa

Gabon

Mr Arsène Mabika-Mabika*, Tuberculosis Laboratory, Bacteriology, Hygiene and Biosecurity, Franceville

Ghana

Dr Anthony Ablordey, Bacteriology Department, Noguchi Memorial Institute for Medical Research, Accra

Ms Bernadette Agbavor, Skin NTD research group, Kumasi Centre for Collaborative Research in Tropical Medicine, KNUST, Kumasi

Dr Adwoa Asante-Poku, Bacteriology Department, Noguchi Memorial Institute for Medical Research, Legon

Dr Lydia Mosi, Department of Biochemistry, Cell and Molecular Biology, University of Ghana, Legon

Professor Richard Phillips, Kumasi Centre for Collaborative Research in Tropical Medicine, KNUST, Kumasi

Ms Mabel Sarpong Duah, West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), University of Ghana, Accra

Liberia

Ms Carmilia Johnson, National Public Health Institute of Liberia (NPHIL), Monrovia

Ms Vera Yatta Walker, National Public Health Institute of Liberia (NPHIL), Monrovia

Nigeria

Professor Pheabian Olaoluwa Akinwale, Molecular Parasitology Research Laboratory, Department of Public Health and Epidemiology, Nigerian Institute of Medical Research, Lagos

Mr Ignatius Ejiofor, St Joseph's Hospital Adazi-Nnukwu, Anambra State

Dr Vincent Pam Gyang, Molecular Parasitology Research Laboratory, Department of Public Health and Epidemiology, Nigerian Institute of Medical Research, Lagos

Togo

Ms Eninam Kouma, Laboratoire de Biologie Moléculaire-Virologie, Institut National d'Hygiène, Lomé

Dr Issaka Maman, Laboratoire de Biologie Moléculaire-Virologie, Institut National d'Hygiène, Lomé

Centre Pasteur du Cameroun

Dr Mirdad Kazanji, Director General, Centre Pasteur du Cameroun, Yaoundé, Cameroon

External laboratory experts (advisers)

Professor Bretzel Gisela,* Division of Infectious Diseases and Tropical Medicine, Ludwig-Maximilians University Munich, Germany

Dr Estelle Marion,* INSERM, PBH IRIS CHU Angers, Angers, France

Dr Sundeep Chaitanya Vedithi, American Leprosy Missions and University of Cambridge, United Kingdom of Great Britain and Northern Ireland

External partners

Dr Alphonse Um Boock, FAIRMED, Yaoundé, Cameroon

Ms Anna Giné, International Cooperation, Anesvad Foundation, Bilbao, Spain

Dr Anthony Obiamaka Meka,* German Leprosy and Tuberculosis Relief Association, Enugu, Nigeria

Mr Smith Afanji, OCEAC/FAIRMED NTD Program, Yaoundé, Cameroon

Dr Earnest Njih Tabah, National Yaws, Leishmaniasis, Leprosy and Buruli ulcer Control Programme, Ministry of Public Health, Yaoundé, Cameroon

Dr Franck Wanda, Centre International de Recherches, d'Enseignements, et de Soins (CIRES), Akonolinga, Cameroon

Other skin NTD experts

Dr Richard Akuffo, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon-Accra, Ghana

Dr Sahar Mubarak Bakhiet (mycetoma),* Department of Molecular Biology, Institute of Endemic Diseases and Laboratory Director, Mycetoma, Research Centre, University of Khartoum, Sudan

Dr Israel Cruz,* National School of Public Health, Instituto de Salud Carlos III, Sinesio Delgado, Spain

Dr Carmen Chicharro Gonzalo, (leishmaniasis),* WHO Collaborating Centre for Leishmaniasis, Instituto de Salud Carlos III, Majadahonda, Spain

Professor Ahmed Fahal (mycetoma), Mycetoma Research Centre, University of Khartoum, Sudan

Dr Javier Moreno (leishmaniasis),* Instituto de Salud Carlos III, Majadahonda, Spain

Dr Wendy van de Sande (mycetoma),* Department of Medical Microbiology & Infectious Diseases, Erasmus Medical Center, Rotterdam, Netherlands

Dr Andy Wende, Xpedite Diagnostics GmbH, Munich, Germany

WHO

Dr Kingsley Asiedu, Prevention, Treatment and Care, WHO Department of Control of Neglected Tropical Diseases, Geneva, Switzerland

Dr Mahoutondji Yves Thierry Barogui, Leprosy, Buruli ulcer & Yaws, Neglected Tropical Diseases, WHO Regional Office for Africa, Libreville, Gabon

Dr Abate Mulugeta Beshah,* Tropical and Vector borne Diseases, WHO Regional Office for Africa, Brazzaville, Congo

Dr Phaniel Habimana, WHO Representative, WHO Country Office, Yaoundé, Cameroon

Dr Augustin Kadima, Tropical and Vector borne Diseases, WHO Regional Office for Africa, Brazzaville, Congo

Dr Etienne Nnomzo'o, WHO Country Office, Yaoundé, Cameroon

Dr Priya Pathak, Prevention, Treatment and Care, WHO Department of Control of Neglected Tropical Diseases, Geneva, Switzerland

***Online participant**

The following participants (listed alphabetically by surname) also joined the meeting online.

Kabiru Mohammed Abass
Gabriella Acquah
Ernesto Afonso
Gideon Akolgo
Abigail Agbanyo
Jennifer Seyram Amedior
Aby Christiane Amon
Margaret Anima Annang
Edwin Ampadu
N'da Kouassi Marcellin Assié
Esther Bikoro
Gisela Bretzel
Okechukwu Chukwuekezie
Tenkeu Daline
Maria Cecília De Almeida
Bahou Roger Dehe
Dziedzom de Souza
Ludovic Ebert
Emilienne Epee
Michael Frimpong
Inès B. Gomido
Balako Gumi
Justice Kyei Boamah

Ijeoma Meka
Mourad Mokni
Patty Mulongo Makimuna
David Coulibaly N'golo
Chijioke Odaghara
Chukwuanugo Ogbuagu
Abimbola Olaitan
Chizaram Onyeaghala
Arantzazu Quintana
Santiago Ramón Garcia
Chandrakant Revankar
Garba Roméo
Malkin Saar
Emma Sáez López
Raoul Saizonou
Sammy Sam-Wobo
Michael Sandel
Shirley Simpson
Igor Tebekem
Tamaz Tsulaia
Stefanie Weiland
Henri Yendjo

BU-LABNET membership certificate



Meeting photographs



© Centre Pasteur du Cameroun

Group photo




© Centre Pasteur du Cameroun



© Centre Pasteur du Cameroun

On-site participation



Online participation

Global Neglected Tropical Diseases Programme
20 Avenue Appia
1211 Geneva 27
Switzerland

neglected.diseases@who.int
<https://www.who.int/teams/control-of-neglected-tropical-diseases>

